Radiation-Induced Liver Damage: Correlation of Histopathology with Hepatobiliary Magnetic Resonance Imaging, a Feasibility Study

CardioVascular and Interventional Radiology

Volumn 38, Issue 1, 2015, Pages 213-221

  Seidensticker, Max ^a   Burak, Miroslaw ^b   Kalinski, Thomas ^a   Garlipp, Benjamin ^a   Koelble, Konrad ^c   Wust, Peter ^d   Antweiler, Kai ^a   Seidensticker, Ricarda ^a   Mohnike, Konrad ^a   Pech, Maciej ^a   Ricke, Jens ^a  

^a Universitatsklinik Magdeburg   (Germany)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gd BOPTA; Gd EOB DTPA; Hepatobiliary contrast media; Radiation induced liver disease

Indexed keywords

GADOBENIC ACID; CONTRAST MEDIUM; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FEASIBILITY STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEPATOBILIARY SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER PARENCHYMA; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INDUCED LIVER DAMAGE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; RADIATION INJURIES; RADIATION RESPONSE; ULTRASTRUCTURE;

AGED; BRACHYTHERAPY; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RADIATION INJURIES;

EID: 84930923850     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-014-0872-7     Document Type: Article

References (44)

1. Boda-Heggemann J, Dinter D, Weiss C, Frauenfeld A, Siebenlist K, Attenberger U, Ottstadt M, Schneider F, Hofheinz RD, Wenz F, Lohr F (2012) Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases–clinical results. Radiat Oncol 7:92
2. Campbell AM, Bailey IH, Burton MA (2001) Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 46(2):487–498
3. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324–331
4. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53(4):810–821
5. de Haen C, Gozzini L (1993) Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 3(1):179–186
6. de Haen C, Lorusso V, Tirone P (1996) Hepatic transport of gadobenate dimeglumine in TR-rats. Acad Radiol 3(Suppl 2):S452–S454
7. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122
8. Fajardo LF, Colby TV (1980) Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 104(11):584–588
9. Farthing MJ, Clark ML, Sloane JP, Powles RL, McElwain TJ (1982) Liver disease after bone marrow transplantation. Gut 23(6):465–474
10. Fox RA, Klemp PF, Egan G, Mina LL, Burton MA, Gray BN (1991) Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys 21(2):463–467
11. Geraci JP, Mariano MS (1993) Radiation hepatology of the rat: parenchymal and nonparenchymal cell injury. Radiat Res 136(2):205–213
12. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, Benito A, Dominguez I, D’Avola D, Herrero JI, Quiroga J, Prieto J, Sangro B (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57(3):1078–1087
13. Grosser OS, Conrad S, Steffen IG, Seidensticker M, Ulrich G, Nultsch M, Furth C, Ricke J, Amthauer H (2012) Therapievalidierung der yttrium-90-radioembolisation durch Bestimmung der Dosisverteilung in einem softwareassistierten workflow. Nuklearmedizin 51:A84
14. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19(1):164–170
15. Herfarth KK, Hof H, Bahner ML, Lohr F, Hoss A, van Kaick G, Wannenmacher M, Debus J (2003) Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 57(2):444–451
16. Jacobs P, Miller JL, Uys CJ, Dietrich BE (1979) Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia. S Afr Med J 55(1):5–10
17. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74(5):1494–1500
18. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60(5):1552–1563
19. Kirchin MA, Pirovano GP, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33(11):798–809
20. Lam MG, Abdelmaksoud MH, Chang DT, Eclov NC, Chung MP, Koong AC, Louie JD, Sze DY (2013) Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys 87(2):323–329
21. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174
22. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31(5):1237–1248
23. Marzola P, Maggioni F, Vicinanza E, Dapra M, Cavagna FM (1997) Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model. J Magn Reson Imaging 7(1):147–152
24. Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, Wust P, Lopez-Hanninen E, Gademann G, Peters N, Berg T, Malfertheiner P, Ricke J (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78(1):172–179
25. Pascolo L, Cupelli F, Anelli PL, Lorusso V, Visigalli M, Uggeri F, Tiribelli C (1999) Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 257(3):746–752
26. Pastor CM, Planchamp C, Pochon S, Lorusso V, Montet X, Mayer J, Terrier F, Vallee JP (2003) Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 229(1):119–125
27. Reed GB Jr, Cox AJ Jr (1966) The human liver after radiation injury A form of veno-occlusive disease. Am J Pathol 48(4):597–611
28. Ricke J, Mohnike K, Pech M, Seidensticker M, Ruhl R, Wieners G, Gaffke G, Kropf S, Felix R, Wust P (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78(2):479–485
29. Ricke J, Seidensticker M, Ludemann L, Pech M, Wieners G, Hengst S, Mohnike K, Cho CH, Lopez Hanninen E, Al-Abadi H, Felix R, Wust P (2005) In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation. Int J Radiat Oncol Biol Phys 62(3):776–784
30. Rohlfing T, West JB, Beier J, Liebig T, Taschner CA, Thomale UW (2000) Registration of functional and anatomical MRI: accuracy assessment and application in navigated neurosurgery. Comput Aided Surg 5(6):414–425
31. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460–466
32. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, Chopitea A, Inarrairaegui M, Arbizu J, Bilbao JI (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112(7):1538–1546
33. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516
34. Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Schitt-Willich H (1993) Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. J Pharm Sci 82(8):799–803
35. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183(1):59–64
36. Seidensticker M, Seidensticker R, Mohnike K, Wybranski C, Kalinski T, Luess S, Pech M, Wust P, Ricke J (2011) Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol 6:40
37. Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, Kettner E, Hildebrandt B, Dudeck O, Pech M, Amthauer H, Ricke J (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 35(5):1066–1073
38. Sempoux C, Horsmans Y, Geubel A, Fraikin J, Van Beers BE, Gigot JF, Lerut J, Rahier J (1997) Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 26(1):128–134
39. Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, Choi JY, Kim KW, Park YN (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22(4):864–871
40. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED (1980) An analysis of hepatic veno occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79(6):1178–1191
41. Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6(5):282–291
42. Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT (2011) Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging–preliminary observations. Radiology 259(1):142–150
43. Wybranski C, Seidensticker M, Mohnike K, Kropf S, Wust P, Ricke J, Ludemann L (2009) In vivo assessment of dose volume and dose gradient effects on the tolerance dose of small liver volumes after single-fraction high-dose-rate 192Ir irradiation. Radiat Res 172(5):598–606
44. Yuan Y, Andronesi OC, Bortfeld TR, Richter C, Wolf R, Guimaraes AR, Hong TS, Seco J (2013) Feasibility study of in vivo MRI based dosimetric verification of proton end-of-range for liver cancer patients. Radiother Oncol 106(3):378–382